The First Affiliated Hospital of Xiamen University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

8 drugs in development

Phase 31

Phase 23

Phase 14

By Therapeutic Area

top 1

Oncology

444%

R&D Momentum

73/100

Pipeline Velocity

39/100

Trial Completion Rate

100/100

Pipeline Concentration

51/100

Pipeline Freshness

69/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners

Activity

Recent Activity

Last 14 days

Oct 27, 2026

Recruiting

Clinical Evaluation of the ACP3-Targeted Dual-Modality PET/Fluorescence Imaging Probe 68Ga-XMFH01 for Preoperative Imaging and Intraoperative Surgical Guidance in Prostate Cancer

Oct 22, 2026

Recruiting

68Ga-XHER2 PET/CT for Noninvasive Assessment of HER2 Expression Across Solid Tumors

Earlier

Oct 21, 2026TrialAn Observational Prospective Cohort Study of Anxiety and Depression in Patients With Hematologic Malignancies

Sep 26, 2026TrialDelta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma

Sep 12, 2026TrialA Prospective Cohort Study of Common Chronic Diseases on Nurses in Xiamen, China: Nurse Cohort Study Xiamen (NCSX)

Sep 11, 2026TrialGlypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma

Aug 28, 2026TrialA Prospective Multi-center Clinical Study on Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma by Multi-dimensional Molecular Imaging

Aug 25, 2026TrialA Multicenter, Prospective, Single-Arm Study of Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

4 more events

Aug 22, 2026TrialA Translational Study of Orelabrutinib Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) as First-Line Treatment for Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Aug 8, 2026TrialTrophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer and Compared With 68Ga-FAPI PET/CT

Aug 7, 2026TrialA Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients With Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Jul 2, 2026TrialDelta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

yFMTPhase 1

Follicular Lymphoma

Chidamide combined with DuvillisibPhase 2

Lymphoma

Chidamide combined with DuvillisibPhase 2

Multiple Myeloma

CAR-T treatmentPhase 2

Non-Small Cell Lung Cancer

Trilaciclib combined with DocetaxelPhase 2

Unknown / Other

Graves Disease

methimazole,Phase 3

Locally Advanced or Metastatic NSCLC

Trilaciclib combined with DocetaxelPhase 2

Newly Diagnosed

D-CMGPhase 1

Post Operative Pain

Intravenous fentanyl 1 μg∙kg-1Phase 1

Treatment

GB5005 CARTPhase 1

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)